Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission
OBJECTIVE: Demonstration of antidepressant efficacy beyond 6 months has infrequently been addressed, and no long-term efficacy data exist for patients with chronic atypical depression. METHOD: Sixty patients with atypical depression (according to Columbia University criteria) of at least 2 years...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1997-01, Vol.154 (1), p.31-36 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 1 |
| container_start_page | 31 |
| container_title | The American journal of psychiatry |
| container_volume | 154 |
| creator | STEWART, J. W TRICAMO, E MCGRATH, P. J QUITKIN, F. M |
| description | OBJECTIVE: Demonstration of antidepressant efficacy beyond 6 months has
infrequently been addressed, and no long-term efficacy data exist for
patients with chronic atypical depression. METHOD: Sixty patients with
atypical depression (according to Columbia University criteria) of at least
2 years' duration and who had improved with imipramine or phenelzine were
stabilized for 6 months and then randomly continued the same medication or
placebo for 6 months. RESULTS: Several baseline differences suggested that
patients who entered the discontinuation trial on a regimen of phenelzine
were more chronically depressed than the imipramine-treated patients.
Survival analysis showed a marked advantage for phenelzine relative to
placebo. In addition, patients switched to placebo from phenelzine
experienced a recurrence of depressive symptoms significantly more often
than patients switched to placebo from imipramine. Patients maintained with
imipramine did not have lower relapse rates than those switched from
imipramine to placebo. Recurrence rates were 23% for patients maintained on
a regimen of phenelzine, 41% for those maintained on a regimen of
imipramine, 47% for those switched from imipramine to placebo, and 87% for
placebo- treated patients originally treated with phenelzine. CONCLUSIONS:
Patients with chronic atypical depression are at high risk of recurrence if
phenelzine is withdrawn 6 months after initial improvement. Similar
findings were not demonstrated for imipramine; this replicates acute trials
demonstrating imipramine's relative ineffectiveness in patients with
atypical depression. Differences in recurrence rates after the switch to
placebo from phenelzine and imipramine could be due to the two drugs'
different mechanisms of action or to baseline differences in the two
populations. |
| doi_str_mv | 10.1176/ajp.154.1.31 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78773434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1518345211</sourcerecordid><originalsourceid>FETCH-LOGICAL-a508t-32639c5b0be489054947a605b6c25a7f8ba32200adff1dc12bcae68fd5071a333</originalsourceid><addsrcrecordid>eNp1kU2r1DAUhoMo13F051YIKopgx3w0TepOLn7BBV0ouCunaUIztklM2sX4S_y5Zu4MFxEli3DOec57XngRekjJjlLZvIJ93FFR7-iO01toQwUXlWRM3UYbQgirWsG_3UX3ct6XknDJLtCFapVqhdigX59TiONhAr04jY21ToM-4GBxHI0300_nDQY_YDe7mGA-ls5jPabgywIsh1g2JjyYmEzOLvjXeHLfzeTGEIajTjJ6Tcl4bXDweHBZB784v8JSYAx2MQk3eC7NMT8v9OyuZe6jOxambB6c_y36-u7tl8sP1dWn9x8v31xVIIhaKs4a3mrRk97UqiWibmsJDRF9o5kAaVUPnDFCYLCWDpqyXoNplB0EkRQ451v07KQbU_ixmrx0xYA20wTehDV3UknJ6_K26PFf4D6syRdvXTlQK8KZKNCT_0FUUMVrwSgt1MsTpVPIORnbxeRmSIeOku6YaVcyLQt1Rzt-xB-dRdd-NsMNfA6xzJ-e55BLFjaB1y7fYMVWI65lXpwwiNH94etfJ38D4mu5EQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1518345211</pqid></control><display><type>article</type><title>Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission</title><source>MEDLINE</source><source>Periodicals Index Online</source><source>American Psychiatric Publishing Journals</source><source>EZB Electronic Journals Library</source><creator>STEWART, J. W ; TRICAMO, E ; MCGRATH, P. J ; QUITKIN, F. M</creator><creatorcontrib>STEWART, J. W ; TRICAMO, E ; MCGRATH, P. J ; QUITKIN, F. M</creatorcontrib><description>OBJECTIVE: Demonstration of antidepressant efficacy beyond 6 months has
infrequently been addressed, and no long-term efficacy data exist for
patients with chronic atypical depression. METHOD: Sixty patients with
atypical depression (according to Columbia University criteria) of at least
2 years' duration and who had improved with imipramine or phenelzine were
stabilized for 6 months and then randomly continued the same medication or
placebo for 6 months. RESULTS: Several baseline differences suggested that
patients who entered the discontinuation trial on a regimen of phenelzine
were more chronically depressed than the imipramine-treated patients.
Survival analysis showed a marked advantage for phenelzine relative to
placebo. In addition, patients switched to placebo from phenelzine
experienced a recurrence of depressive symptoms significantly more often
than patients switched to placebo from imipramine. Patients maintained with
imipramine did not have lower relapse rates than those switched from
imipramine to placebo. Recurrence rates were 23% for patients maintained on
a regimen of phenelzine, 41% for those maintained on a regimen of
imipramine, 47% for those switched from imipramine to placebo, and 87% for
placebo- treated patients originally treated with phenelzine. CONCLUSIONS:
Patients with chronic atypical depression are at high risk of recurrence if
phenelzine is withdrawn 6 months after initial improvement. Similar
findings were not demonstrated for imipramine; this replicates acute trials
demonstrating imipramine's relative ineffectiveness in patients with
atypical depression. Differences in recurrence rates after the switch to
placebo from phenelzine and imipramine could be due to the two drugs'
different mechanisms of action or to baseline differences in the two
populations.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.154.1.31</identifier><identifier>PMID: 8988955</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Antidepressants ; Biological and medical sciences ; Chronic Disease ; Depressive Disorder - diagnosis ; Depressive Disorder - drug therapy ; Depressive Disorder - prevention & control ; Drug Administration Schedule ; Female ; Humans ; Imipramine - therapeutic use ; Male ; Medical sciences ; Mental depression ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Phenelzine - therapeutic use ; Placebos ; Psychiatric Status Rating Scales - statistics & numerical data ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Recurrence ; Reproducibility of Results ; Survival Analysis ; Treatment Outcome</subject><ispartof>The American journal of psychiatry, 1997-01, Vol.154 (1), p.31-36</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Jan 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a508t-32639c5b0be489054947a605b6c25a7f8ba32200adff1dc12bcae68fd5071a333</citedby><cites>FETCH-LOGICAL-a508t-32639c5b0be489054947a605b6c25a7f8ba32200adff1dc12bcae68fd5071a333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.154.1.31$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.154.1.31$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>315,781,785,2856,4025,21631,21632,21633,27874,27928,27929,27930,77799,77804</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2536531$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8988955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEWART, J. W</creatorcontrib><creatorcontrib>TRICAMO, E</creatorcontrib><creatorcontrib>MCGRATH, P. J</creatorcontrib><creatorcontrib>QUITKIN, F. M</creatorcontrib><title>Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: Demonstration of antidepressant efficacy beyond 6 months has
infrequently been addressed, and no long-term efficacy data exist for
patients with chronic atypical depression. METHOD: Sixty patients with
atypical depression (according to Columbia University criteria) of at least
2 years' duration and who had improved with imipramine or phenelzine were
stabilized for 6 months and then randomly continued the same medication or
placebo for 6 months. RESULTS: Several baseline differences suggested that
patients who entered the discontinuation trial on a regimen of phenelzine
were more chronically depressed than the imipramine-treated patients.
Survival analysis showed a marked advantage for phenelzine relative to
placebo. In addition, patients switched to placebo from phenelzine
experienced a recurrence of depressive symptoms significantly more often
than patients switched to placebo from imipramine. Patients maintained with
imipramine did not have lower relapse rates than those switched from
imipramine to placebo. Recurrence rates were 23% for patients maintained on
a regimen of phenelzine, 41% for those maintained on a regimen of
imipramine, 47% for those switched from imipramine to placebo, and 87% for
placebo- treated patients originally treated with phenelzine. CONCLUSIONS:
Patients with chronic atypical depression are at high risk of recurrence if
phenelzine is withdrawn 6 months after initial improvement. Similar
findings were not demonstrated for imipramine; this replicates acute trials
demonstrating imipramine's relative ineffectiveness in patients with
atypical depression. Differences in recurrence rates after the switch to
placebo from phenelzine and imipramine could be due to the two drugs'
different mechanisms of action or to baseline differences in the two
populations.</description><subject>Adult</subject><subject>Antidepressants</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - prevention & control</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Imipramine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenelzine - therapeutic use</subject><subject>Placebos</subject><subject>Psychiatric Status Rating Scales - statistics & numerical data</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Recurrence</subject><subject>Reproducibility of Results</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp1kU2r1DAUhoMo13F051YIKopgx3w0TepOLn7BBV0ouCunaUIztklM2sX4S_y5Zu4MFxEli3DOec57XngRekjJjlLZvIJ93FFR7-iO01toQwUXlWRM3UYbQgirWsG_3UX3ct6XknDJLtCFapVqhdigX59TiONhAr04jY21ToM-4GBxHI0300_nDQY_YDe7mGA-ls5jPabgywIsh1g2JjyYmEzOLvjXeHLfzeTGEIajTjJ6Tcl4bXDweHBZB784v8JSYAx2MQk3eC7NMT8v9OyuZe6jOxambB6c_y36-u7tl8sP1dWn9x8v31xVIIhaKs4a3mrRk97UqiWibmsJDRF9o5kAaVUPnDFCYLCWDpqyXoNplB0EkRQ451v07KQbU_ixmrx0xYA20wTehDV3UknJ6_K26PFf4D6syRdvXTlQK8KZKNCT_0FUUMVrwSgt1MsTpVPIORnbxeRmSIeOku6YaVcyLQt1Rzt-xB-dRdd-NsMNfA6xzJ-e55BLFjaB1y7fYMVWI65lXpwwiNH94etfJ38D4mu5EQ</recordid><startdate>19970101</startdate><enddate>19970101</enddate><creator>STEWART, J. W</creator><creator>TRICAMO, E</creator><creator>MCGRATH, P. J</creator><creator>QUITKIN, F. M</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19970101</creationdate><title>Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission</title><author>STEWART, J. W ; TRICAMO, E ; MCGRATH, P. J ; QUITKIN, F. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a508t-32639c5b0be489054947a605b6c25a7f8ba32200adff1dc12bcae68fd5071a333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Antidepressants</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - prevention & control</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Imipramine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenelzine - therapeutic use</topic><topic>Placebos</topic><topic>Psychiatric Status Rating Scales - statistics & numerical data</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Recurrence</topic><topic>Reproducibility of Results</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEWART, J. W</creatorcontrib><creatorcontrib>TRICAMO, E</creatorcontrib><creatorcontrib>MCGRATH, P. J</creatorcontrib><creatorcontrib>QUITKIN, F. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEWART, J. W</au><au>TRICAMO, E</au><au>MCGRATH, P. J</au><au>QUITKIN, F. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1997-01-01</date><risdate>1997</risdate><volume>154</volume><issue>1</issue><spage>31</spage><epage>36</epage><pages>31-36</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: Demonstration of antidepressant efficacy beyond 6 months has
infrequently been addressed, and no long-term efficacy data exist for
patients with chronic atypical depression. METHOD: Sixty patients with
atypical depression (according to Columbia University criteria) of at least
2 years' duration and who had improved with imipramine or phenelzine were
stabilized for 6 months and then randomly continued the same medication or
placebo for 6 months. RESULTS: Several baseline differences suggested that
patients who entered the discontinuation trial on a regimen of phenelzine
were more chronically depressed than the imipramine-treated patients.
Survival analysis showed a marked advantage for phenelzine relative to
placebo. In addition, patients switched to placebo from phenelzine
experienced a recurrence of depressive symptoms significantly more often
than patients switched to placebo from imipramine. Patients maintained with
imipramine did not have lower relapse rates than those switched from
imipramine to placebo. Recurrence rates were 23% for patients maintained on
a regimen of phenelzine, 41% for those maintained on a regimen of
imipramine, 47% for those switched from imipramine to placebo, and 87% for
placebo- treated patients originally treated with phenelzine. CONCLUSIONS:
Patients with chronic atypical depression are at high risk of recurrence if
phenelzine is withdrawn 6 months after initial improvement. Similar
findings were not demonstrated for imipramine; this replicates acute trials
demonstrating imipramine's relative ineffectiveness in patients with
atypical depression. Differences in recurrence rates after the switch to
placebo from phenelzine and imipramine could be due to the two drugs'
different mechanisms of action or to baseline differences in the two
populations.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>8988955</pmid><doi>10.1176/ajp.154.1.31</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1997-01, Vol.154 (1), p.31-36 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78773434 |
| source | MEDLINE; Periodicals Index Online; American Psychiatric Publishing Journals; EZB Electronic Journals Library |
| subjects | Adult Antidepressants Biological and medical sciences Chronic Disease Depressive Disorder - diagnosis Depressive Disorder - drug therapy Depressive Disorder - prevention & control Drug Administration Schedule Female Humans Imipramine - therapeutic use Male Medical sciences Mental depression Middle Aged Neuropharmacology Pharmacology. Drug treatments Phenelzine - therapeutic use Placebos Psychiatric Status Rating Scales - statistics & numerical data Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Recurrence Reproducibility of Results Survival Analysis Treatment Outcome |
| title | Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T16%3A32%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prophylactic%20efficacy%20of%20phenelzine%20and%20imipramine%20in%20chronic%20atypical%20depression:%20likelihood%20of%20recurrence%20on%20discontinuation%20after%206%20months'%20remission&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=STEWART,%20J.%20W&rft.date=1997-01-01&rft.volume=154&rft.issue=1&rft.spage=31&rft.epage=36&rft.pages=31-36&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.154.1.31&rft_dat=%3Cproquest_cross%3E1518345211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1518345211&rft_id=info:pmid/8988955&rfr_iscdi=true |